Summary statistics - quantitative results

EQA round: RFA2/26 - Risk Factors for Atherosclerosis

Deadline: 2.10.2026

Setup: groups - M (measurement principle); minimal size of the groups n = 5

RoM = robust average
SD = standard deviation
CV = coefficient of variation
N_{tot} = total number of the results
N_{out} = number of the results removed before calculation
AV = assigned value
CVP = consensus of all participants
CVPG = consensus of the participants' groups
U_{AV} = expanded uncertainty of the assigned value (k = 2)
D_{max} = acceptable difference
LL = lower limit
UL = upper limit
N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
(114) **Apolipoprotein AI**	[g/L]				95								95	90	95
Sample A		2,15	0,099	4,6	95		CVP	2,15	0,025	17%	1,78	2,52	95	90	95
(2) Immunoturbidimetry		2,15	0,098	4,5	89	0							89		
(3) Immunonephelometry		2,16	0,082	3,8	5	0							5		
Other					1	0							1		
							1x 0								
Sample B		1,06	0,06	5,7	95		CVP	1,06	0,015	17%	0,879	1,25	95	92	97
(2) Immunoturbidimetry		1,05	0,059	5,6	89	0							89		
(3) Immunonephelometry		1,19	0,16	13	5	0							5		
Other					1	0							1		
							1x 0								
(115) **Apolipoprotein B**	[g/L]				116								116	111	96
Sample A		1,25	0,061	4,9	116		CVP	1,25	0,014	14%	1,07	1,43	116	112	97
(2) Immunoturbidimetry		1,25	0,059	4,7	111	0							111		
Other					5	0							5		
							1x 0, 4x 3								
Sample B		0,635	0,032	5	116		CVP	0,635	0,007	14%	0,546	0,724	116	111	96
(2) Immunoturbidimetry		0,635	0,032	5	111	0							111		
Other					5	0							5		
							1x 0, 4x 3								
(111) **Cholesterol**	[mmol/L]				320								320	312	98
Sample A													320	315	98
(0) Not specified		6,91	0,19	2,8	320	0	CVP	6,91	0,026	8%	6,35	7,47	320		
Sample B													320	312	98
(0) Not specified		3,4	0,1	2,9	320	0	CVP	3,4	0,014	8%	3,12	3,68	320		
(113) **Cholesterol HDL**	[mmol/L]				325								325	317	98
Sample A		1,96	0,092	4,7	325		CVP	1,96	0,013	15%	1,66	2,26	325	318	98
(2) Direct determination		1,96	0,092	4,7	321	0							321		
Other					4	0							4		
							3x 1, 1x 99								
Sample B		0,958	0,038	4	325		CVP	0,958	0,005	15%	0,814	1,11	325	319	98
(2) Direct determination		0,958	0,038	4	321	0							321		
Other					4	0							4		
							3x 1, 1x 99								
(118) **Cholesterol LDL (direct determination)**	[mmol/L]				279								279	272	97
Sample A													279	272	97
(0) Not specified		4,06	0,38	9,4	279	0	CVP	4,06	0,056	20%	3,24	4,88	279		
Sample B													279	275	99
(0) Not specified		2,03	0,15	7,6	279	0	CVP	2,03	0,023	20%	1,62	2,44	279		
(116) **Cholesterol LDL (calculation)**	[mmol/L]				95								95	94	99
Sample A													95	94	99
(0) Not specified		4,09	0,16	3,9	95	0	CVP	4,09	0,04	15%	3,47	4,71	95		
Sample B													95	94	99
(0) Not specified		1,99	0,1	5,2	95	0	CVP	1,99	0,026	15%	1,69	2,29	95		
(117) **Lipoprotein (a) [g/L]**	[g/L]				42								42	40	95
Sample A		0,325	0,022	6,9	42		CVP	0,325	0,009	25%	0,243	0,407	42	42	100
(2) Immunoturbidimetry		0,326	0,022	6,7	41	0							41		
Other					1	0							1		
							1x 0								
Sample B		0,167	0,022	13	42		CVP	0,167	0,008	25%	0,125	0,209	42	40	95
(2) Immunoturbidimetry		0,168	0,021	12	41	0							41		
Other					1	0							1		
							1x 0								
(119) **Lipoprotein (a) [nmol/L]**	[nmol/L]				89								89	70	79
Sample A		63,6	9,3	15	89								89	77	87
(2) Immunoturbidimetry		70,8	6,8	9,6	39	0	CVP	70,2	2,8	20%	56,1	84,3	39		
(2) Immunoturbidimetry; (60) Roche		58,6	4,8	8,1	48	0	CVPG	58,6	1,7	16%	49,2	68	48		
Other					2	0							2		
							1x 0, 1x 3								
Sample B		30	7,7	26	89								89	72	81
(2) Immunoturbidimetry		36,2	5,1	14	39	0	CVP	35,7	2,1	20%	28,5	42,9	39		
(2) Immunoturbidimetry; (60) Roche		24,8	3	12	48	0	CVPG	24,8	1,1	16%	20,8	28,8	48		
Other					2	0							2		
							1x 0, 1x 3								

Summary statistics - quantitative results

EQA round: RFA2/26 - Risk Factors for Atherosclerosis

Deadline: 2.10.2026

Setup: groups - M (measurement principle); minimal size of the groups n = 5

Test / Sample / Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
(112) **Triacylglycerols**	[mmol/L]				321								321	316	98
Sample A		2,04	0,058	2,8	321		CVP	2,04	0,008	13%	1,77	2,31	321	317	99
(1) Photometric enzyme (GPO-PAP)		2,05	0,058	2,8	305	0							305		
(2) Enzymatic UV method		2,03	0,057	2,8	15	0							15		
Other					1	0							1		
							1x 99								
Sample B		1,04	0,042	4	321		CVP	1,04	0,006	13%	0,904	1,18	321	316	98
(1) Photometric enzyme (GPO-PAP)		1,04	0,042	4	305	0							305		
(2) Enzymatic UV method		1,03	0,038	3,7	15	0							15		
Other					1	0							1		
							1x 99								